Advanced

Costs and quality of life for psoriatic patients at different degrees of severity in southern Sweden - a cross-sectional study.

Ghatnekar, Ola; Ljungberg, Anders; Wirestrand, Lars-Erik and Svensson, Åke LU (2012) In EJD. European Journal of Dermatology 22(2). p.238-245
Abstract
Objectives: Knowledge of the societal costs of psoriasis is limited. This study estimated the cost of care, psoriasis area and severity index (PASI), and quality of life in a defined patient population in Sweden. Methods: A prevalence-based prospective recruitment of patients visiting two Swedish dermatology clinics between September and December 2009 was performed, collecting resource utilization for health care contacts, treatment, travelling, and productivity loss during 1 month. Results: 164 patients were included. Mean total cost per patient-month was 994€. Main cost drivers were outpatient visits and light therapy (49%), biological drugs (20%) and productivity loss (22%). Total cost for topical treatment only (TT; 34%) was 369€,... (More)
Objectives: Knowledge of the societal costs of psoriasis is limited. This study estimated the cost of care, psoriasis area and severity index (PASI), and quality of life in a defined patient population in Sweden. Methods: A prevalence-based prospective recruitment of patients visiting two Swedish dermatology clinics between September and December 2009 was performed, collecting resource utilization for health care contacts, treatment, travelling, and productivity loss during 1 month. Results: 164 patients were included. Mean total cost per patient-month was 994€. Main cost drivers were outpatient visits and light therapy (49%), biological drugs (20%) and productivity loss (22%). Total cost for topical treatment only (TT; 34%) was 369€, light therapy (LT; 24%) 1,274€, traditional systemic treatment (TST; 26%) 1,085€ and biological systemic treatment (BST; 16%) 1,709€ per patient-month. Main cost drivers were: outpatient visits (56%) in TT as well as for LT (78%), productivity loss (40%) in TST, and biological drugs (71%) among BST patients. There was no clear relationship between clinical (PASI) or subjective (DLQI) severity estimations and costs. Conclusions: The one-month cost-of-illness amounted to almost 1,000€/month, with great variations. Despite 1,190€ difference in drug cost for TST vs BST, total cost per month differed by 623€ because of offsets from improved productivity. A trend towards lower severity and reductions in outpatient and topical treatment costs was seen. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
EJD. European Journal of Dermatology
volume
22
issue
2
pages
238 - 245
publisher
John Libbey Eurotext
external identifiers
  • WOS:000302908700014
  • PMID:22361745
  • Scopus:84859755815
ISSN
1167-1122
DOI
10.1684/ejd.2011.1635
language
English
LU publication?
yes
id
a87886c3-82ce-4976-bea4-800b8ed7635a (old id 2432544)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/22361745?dopt=Abstract
date added to LUP
2012-04-02 10:47:58
date last changed
2017-01-01 07:44:28
@article{a87886c3-82ce-4976-bea4-800b8ed7635a,
  abstract     = {Objectives: Knowledge of the societal costs of psoriasis is limited. This study estimated the cost of care, psoriasis area and severity index (PASI), and quality of life in a defined patient population in Sweden. Methods: A prevalence-based prospective recruitment of patients visiting two Swedish dermatology clinics between September and December 2009 was performed, collecting resource utilization for health care contacts, treatment, travelling, and productivity loss during 1 month. Results: 164 patients were included. Mean total cost per patient-month was 994€. Main cost drivers were outpatient visits and light therapy (49%), biological drugs (20%) and productivity loss (22%). Total cost for topical treatment only (TT; 34%) was 369€, light therapy (LT; 24%) 1,274€, traditional systemic treatment (TST; 26%) 1,085€ and biological systemic treatment (BST; 16%) 1,709€ per patient-month. Main cost drivers were: outpatient visits (56%) in TT as well as for LT (78%), productivity loss (40%) in TST, and biological drugs (71%) among BST patients. There was no clear relationship between clinical (PASI) or subjective (DLQI) severity estimations and costs. Conclusions: The one-month cost-of-illness amounted to almost 1,000€/month, with great variations. Despite 1,190€ difference in drug cost for TST vs BST, total cost per month differed by 623€ because of offsets from improved productivity. A trend towards lower severity and reductions in outpatient and topical treatment costs was seen.},
  author       = {Ghatnekar, Ola and Ljungberg, Anders and Wirestrand, Lars-Erik and Svensson, Åke},
  issn         = {1167-1122},
  language     = {eng},
  number       = {2},
  pages        = {238--245},
  publisher    = {John Libbey Eurotext},
  series       = {EJD. European Journal of Dermatology},
  title        = {Costs and quality of life for psoriatic patients at different degrees of severity in southern Sweden - a cross-sectional study.},
  url          = {http://dx.doi.org/10.1684/ejd.2011.1635},
  volume       = {22},
  year         = {2012},
}